Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors | Caris Life Sciences
Portal
Order
Home / Research / Publications / Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors

Publications

Back

Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors

– Caris Life Sciences

Poster

Key Finding:

Biomarkers of immune checkpoint inhibitor response, like PD-L1 and tumor mutational burden, have low prevalence in uveal melanoma and are not associated with benefit from immune blockade. 

Download Publication

Discover
More

  • Multi-Omics and Immune Cell Profiling of Metastatic Uveal Melanomas

    – Caris Life Sciences

    Poster

    Background Uveal melanoma (UM) is a rare tumor of the eye which is biologically distinct from cutaneous melanoma (CM). Treatment options for patients with metastatic… […]

  • Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma

    – Caris Life Sciences

    Poster

    The purpose of this study is to investigate differences in expression of PD-L1 on tumor cells and PD-1 receptor on tumor infiltrating lymphocytes (TILs) between… […]
Learn More

Ready to Get Started on the Journey?

Name(Required)